Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity.

Zhou D, Casavant J, Graziani EI, He H, Janso J, Loganzo F, Musto S, Tumey N, O'Donnell CJ, Dushin R.

Bioorg Med Chem Lett. 2019 Apr 1;29(7):943-947. doi: 10.1016/j.bmcl.2019.01.009. Epub 2019 Jan 11.

PMID:
30655215
2.

Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates.

Ratnayake AS, Chang LP, Tumey LN, Loganzo F, Chemler JA, Wagenaar M, Musto S, Li F, Janso JE, Ballard TE, Rago B, Steele GL, Ding W, Feng X, Hosselet C, Buklan V, Lucas J, Koehn FE, O'Donnell CJ, Graziani EI.

Bioconjug Chem. 2019 Jan 16;30(1):200-209. doi: 10.1021/acs.bioconjchem.8b00843. Epub 2018 Dec 13.

PMID:
30543418
3.

Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.

Shah DK, Loganzo F, Haddish-Berhane N, Musto S, Wald HS, Barletta F, Lucas J, Clark T, Hansel S, Betts A.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):339-349. doi: 10.1007/s10928-018-9577-x. Epub 2018 Feb 8.

PMID:
29423862
4.

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).

Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, Tylaska L, King L, Zhou D, Dushin R, Myers JS, Rosfjord E, Lucas J, Gerber HP, Loganzo F.

Mol Cancer Ther. 2018 Jan;17(1):243-253. doi: 10.1158/1535-7163.MCT-17-0403. Epub 2017 Oct 20.

5.

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.

Puthenveetil S, He H, Loganzo F, Musto S, Teske J, Green M, Tan X, Hosselet C, Lucas J, Tumey LN, Sapra P, Subramanyam C, O'Donnell CJ, Graziani EI.

PLoS One. 2017 May 30;12(5):e0178452. doi: 10.1371/journal.pone.0178452. eCollection 2017.

6.

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L.

AAPS J. 2017 Jul;19(4):1123-1135. doi: 10.1208/s12248-017-0083-7. Epub 2017 Apr 24.

PMID:
28439809
7.

Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

Leverett CA, Sukuru SC, Vetelino BC, Musto S, Parris K, Pandit J, Loganzo F, Varghese AH, Bai G, Liu B, Liu D, Hudson S, Doppalapudi VR, Stock J, O'Donnell CJ, Subramanyam C.

ACS Med Chem Lett. 2016 Aug 26;7(11):999-1004. eCollection 2016 Nov 10.

8.

Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SC, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O'Donnell CJ, Subramanyam C.

ACS Med Chem Lett. 2016 Jun 22;7(11):977-982. eCollection 2016 Nov 10.

9.

Mechanisms of Resistance to Antibody-Drug Conjugates.

Loganzo F, Sung M, Gerber HP.

Mol Cancer Ther. 2016 Dec;15(12):2825-2834. Epub 2016 Oct 25. Review.

10.

Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.

Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, Musto S, Clark T, Rago B, Koehn F, Veneziale R, Falahaptisheh H, Han X, Barletta F, Lucas J, Subramanyam C, O'Donnell CJ, Tumey LN, Sapra P, Gerber HP, Ma D, Graziani EI.

Bioconjug Chem. 2016 Aug 17;27(8):1880-8. doi: 10.1021/acs.bioconjchem.6b00291. Epub 2016 Jul 28.

PMID:
27412791
11.

Determination of Antibody-Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation.

Bessire AJ, Ballard TE, Charati M, Cohen J, Green M, Lam MH, Loganzo F, Nolting B, Pierce B, Puthenveetil S, Roberts L, Schildknegt K, Subramanyam C.

Bioconjug Chem. 2016 Jul 20;27(7):1645-54. doi: 10.1021/acs.bioconjchem.6b00192. Epub 2016 Jun 13.

PMID:
27206324
12.

Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.

Puthenveetil S, Musto S, Loganzo F, Tumey LN, O'Donnell CJ, Graziani E.

Bioconjug Chem. 2016 Apr 20;27(4):1030-9. doi: 10.1021/acs.bioconjchem.6b00054. Epub 2016 Mar 22.

PMID:
26942771
13.

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

Gerber HP, Sapra P, Loganzo F, May C.

Biochem Pharmacol. 2016 Feb 15;102:1-6. doi: 10.1016/j.bcp.2015.12.008. Epub 2015 Dec 11. Review.

PMID:
26686577
14.

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.

Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, Lam MH, Hu W, Charati MB, Khandke K, Kim KS, Cinque M, Lucas J, Graziani E, Maderna A, O'Donnell CJ, Arndt KT, Gerber HP.

Mol Cancer Ther. 2015 Apr;14(4):952-63. doi: 10.1158/1535-7163.MCT-14-0862. Epub 2015 Feb 2.

15.

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.

Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, Chen Z, Risley H, Parris K, Pandit J, Varghese AH, Shanker S, Song C, Sukuru SC, Farley KA, Wagenaar MM, Shapiro MJ, Musto S, Lam MH, Loganzo F, O'Donnell CJ.

J Med Chem. 2014 Dec 26;57(24):10527-43. doi: 10.1021/jm501649k. Epub 2014 Dec 9.

PMID:
25431858
16.

Borrelidin B: isolation, biological activity, and implications for nitrile biosynthesis.

Schulze CJ, Bray WM, Loganzo F, Lam MH, Szal T, Villalobos A, Koehn FE, Linington RG.

J Nat Prod. 2014 Nov 26;77(11):2570-4. doi: 10.1021/np500727g. Epub 2014 Nov 13.

PMID:
25393949
17.

Synthesis, molecular editing, and biological assessment of the potent cytotoxin leiodermatolide.

Mailhol D, Willwacher J, Kausch-Busies N, Rubitski EE, Sobol Z, Schuler M, Lam MH, Musto S, Loganzo F, Maderna A, Fürstner A.

J Am Chem Soc. 2014 Nov 5;136(44):15719-29. doi: 10.1021/ja508846g. Epub 2014 Oct 27.

PMID:
25347620
18.

Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy.

Tumey LN, Charati M, He T, Sousa E, Ma D, Han X, Clark T, Casavant J, Loganzo F, Barletta F, Lucas J, Graziani EI.

Bioconjug Chem. 2014 Oct 15;25(10):1871-80. doi: 10.1021/bc500357n. Epub 2014 Oct 6.

PMID:
25216346
19.

Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues.

He H, Ratnayake AS, Janso JE, He M, Yang HY, Loganzo F, Shor B, O'Donnell CJ, Koehn FE.

J Nat Prod. 2014 Aug 22;77(8):1864-70. doi: 10.1021/np500342m.

PMID:
25098528
20.

New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.

Chen Z, Maderna A, Sukuru SC, Wagenaar M, O'Donnell CJ, Lam MH, Musto S, Loganzo F.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6688-94. doi: 10.1016/j.bmcl.2013.10.039. Epub 2013 Oct 29.

PMID:
24210503
21.

Total syntheses and biological reassessment of lactimidomycin, isomigrastatin and congener glutarimide antibiotics.

Micoine K, Persich P, Llaveria J, Lam MH, Maderna A, Loganzo F, Fürstner A.

Chemistry. 2013 Jun 3;19(23):7370-83. doi: 10.1002/chem.201300393. Epub 2013 Apr 17.

PMID:
23595541
22.

Depsides isolated from the Sri Lankan lichen Parmotrema sp. exhibit selective Plk1 inhibitory activity.

Williams DE, Loganzo F, Whitney L, Togias J, Harrison R, Singh MP, McDonald LA, Kathirgamanathar S, Karunaratne V, Andersen RJ.

Pharm Biol. 2011 Mar;49(3):296-301. doi: 10.3109/13880209.2010.517540. Epub 2011 Feb 1.

PMID:
21281249
23.

Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.

Sellar G, Alvarez JD, Loganzo F, Abbas R, Immermann F, Karnoub M, Feuerstein GZ, Burczynski ME, Coughlin CM.

Biomark Med. 2008 Apr;2(2):147-53. doi: 10.2217/17520363.2.2.147.

PMID:
20477436
24.

Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, Nittoli T, Ravi MR, Tan X, Loganzo F.

Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. Epub 2007 Mar 23.

PMID:
17416531
25.

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.

Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM.

Mol Cancer Ther. 2006 Feb;5(2):270-8.

26.

Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.

Zask A, Kaplan J, Musto S, Loganzo F.

J Am Chem Soc. 2005 Dec 21;127(50):17667-71.

PMID:
16351096
27.

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, Nittoli T, Dushin RG, Discafani C, Nilakantan R, Marini J, Ravi M, Cheung K, Tan X, Musto S, Annable T, Siegel MM, Loganzo F.

J Med Chem. 2005 Dec 1;48(24):7560-81.

PMID:
16302797
28.

Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.

Nunes M, Kaplan J, Wooters J, Hari M, Minnick AA Jr, May MK, Shi C, Musto S, Beyer C, Krishnamurthy G, Qiu Y, Loganzo F, Ayral-Kaloustian S, Zask A, Greenberger LM.

Biochemistry. 2005 May 10;44(18):6844-57.

PMID:
15865430
29.

Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.

Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T.

Biochemistry. 2004 Nov 9;43(44):13944-54.

PMID:
15518543
30.

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM.

Mol Cancer Ther. 2004 Oct;3(10):1319-27.

31.

Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.

Yamashita A, Norton EB, Kaplan JA, Niu C, Loganzo F, Hernandez R, Beyer CF, Annable T, Musto S, Discafani C, Zask A, Ayral-Kaloustian S.

Bioorg Med Chem Lett. 2004 Nov 1;14(21):5317-22.

PMID:
15454219
32.

Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, Khafizova G, Musto S, Hernandez R, Annable T, Yang X, Discafani C, Beyer C, Greenberger LM, Loganzo F, Ayral-Kaloustian S.

J Med Chem. 2004 Sep 9;47(19):4774-86.

PMID:
15341492
33.

D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors.

Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Yamashita A, Beyer C, Krishnamurthy G, Greenberger LM, Loganzo F, Ayral-Kaloustian S.

Bioorg Med Chem Lett. 2004 Aug 16;14(16):4353-8.

PMID:
15261301
34.

Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents.

Niu C, Smith D, Zask A, Loganzo F, Discafani C, Beyer C, Greenberger L, Ayral-Kaloustian S.

Bioorg Med Chem Lett. 2004 Aug 16;14(16):4329-32.

PMID:
15261296
35.

Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.

Wissner A, Hamann PR, Nilakantan R, Greenberger LM, Ye F, Rapuano TA, Loganzo F.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1411-6.

PMID:
15006373
36.

Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents.

Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, Loganzo F, Greenberger L, Barkoczy J, Pettit GR, Smith AB 3rd, Gurulingappa H, Khan S, Parmigiani G, Kinzler KW, Zhou S, Vogelstein B.

Cancer Biol Ther. 2004 Mar;3(3):326-37. Epub 2004 Mar 12.

PMID:
14739784
37.

Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules.

Krishnamurthy G, Cheng W, Lo MC, Aulabaugh A, Razinkov V, Ding W, Loganzo F, Zask A, Ellestad G.

Biochemistry. 2003 Nov 25;42(46):13484-95.

PMID:
14621994
38.

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM.

Mol Cancer Ther. 2003 Sep;2(9):873-84.

39.

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM.

Cancer Res. 2003 Apr 15;63(8):1838-45.

40.

Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells.

Bocchia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, Albino AP, Scheinberg DA.

Leuk Res. 1997 May;21(5):439-47.

PMID:
9225073
41.

Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers.

Papandreou CN, Bogenrieder T, Loganzo F, Albino AP, Nanus DM.

Urology. 1997 Mar;49(3):481-6.

PMID:
9123723
42.

Mutation and expression of the low affinity neurotrophin receptor in human malignant melanoma.

Papandreou C, Bogenrieder T, Loganzo F, Chao MV, Nanus DM, Albino AP.

Melanoma Res. 1996 Oct;6(5):373-8.

PMID:
8908597
43.

Catalytic activity of the SH2 domain of human pp60c-src; evidence from NMR, mass spectrometry, site-directed mutagenesis and kinetic studies for an inherent phosphatase activity.

Boerner RJ, Consler TG, Gampe RT Jr, Weigl D, Willard DH, Davis DG, Edison AM, Loganzo F Jr, Kassel DB, Xu RX, et al.

Biochemistry. 1995 Nov 21;34(46):15351-8.

PMID:
7578151
44.

Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.

Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F Jr, Kelsen DP, Fuks Z, Albino AP.

J Natl Cancer Inst. 1995 Sep 20;87(18):1394-9.

PMID:
7658500
45.

Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas.

Vidal MJ, Loganzo F Jr, de Oliveira AR, Hayward NK, Albino AP.

Melanoma Res. 1995 Aug;5(4):243-50.

PMID:
7496159
46.

Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.

Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, et al.

Cancer Res. 1995 Jul 1;55(13):2713-8.

47.

The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.

Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP.

Int J Cancer. 1995 Feb 20;64(1):37-46.

PMID:
7665247
48.

Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.

Loganzo F Jr, Dosik JS, Zhao Y, Vidal MJ, Nanus DM, Sudol M, Albino AP.

Oncogene. 1993 Oct;8(10):2637-44.

PMID:
7690926

Supplemental Content

Loading ...
Support Center